Compounded GLP-1 Ruling 2026: Fifth Circuit Backs FDA Delisting

Is compounded semaglutide legal? As of August 27, 2026, bulk-compounded semaglutide is no longer lawful for general use, but patient-specific compounding for an individual with a documented medical need remains legal. The U.S. Court of Appeals for the Fifth Circuit on Aug. 27 affirmed the FDA’s removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list, ending the legal basis for pharmacies and outsourcing facilities to mass-produce copycat versions of the blockbuster GLP-1 drugs. The companion opinion in the tirzepatide case reached the same result the same day.

This article is informational and is not medical or legal advice. It does not recommend any product, dose, or prescriber. Consult a licensed healthcare provider and, where relevant, an attorney for your specific situation.

Key answers at a glance

Is compounded semaglutide still legal 2026? No, not as a general matter. The Fifth Circuit’s August 27, 2026 ruling upheld the FDA’s shortage delisting, so bulk compounding of semaglutide for general use is no longer lawful. Patient-specific 503A compounding for an individual with a documented medical need remains legal.

Can I still get compounded Ozempic? Only through patient-specific compounding. A pharmacy can no longer mass-produce a copy of the Ozempic brand on a shortage rationale, but a prescriber can still write an individual prescription for compounded semaglutide when there is a documented clinical need.

What is the compounded GLP-1 ruling? The Fifth Circuit affirmed the FDA’s removal of semaglutide and tirzepatide from the national shortage list (cases 25-10758 and 25-10600), ending bulk GLP-1 compounding for general use while preserving patient-specific 503A compounding.

Compounded semaglutide 2026: is it still available? Not as a mass-produced, shortage-based product. As of August 27, 2026, only patient-specific compounding under the 503A pathway — with a valid prescription and a documented medical need — remains available.

What the Fifth Circuit ruled

In two unpublished per curiam opinions issued the same day by the same panel — Judges Richman, Duncan, and Oldham — the Fifth Circuit affirmed the district courts and upheld the FDA’s delisting decisions in both appeals:

• Case 25-10600 (tirzepatide): Eli Lilly’s Mounjaro and Zepbound. Affirmed.
• Case 25-10758 (semaglutide): Novo Nordisk’s Ozempic and Wegovy. Affirmed.

Each opinion concluded: “For the foregoing reasons, we AFFIRM the district court’s judgment.” The litigation was brought by the Outsourcing Facilities Association and North American Custom Laboratories (FarmaKeio), which had challenged the FDA’s conclusion that the shortages were resolved. Law360 reported that the FDA “did not unlawfully remove blockbuster GLP-1 medications” from the shortage list, “handing a loss to compounding pharmacies that produce copycat doses of the drugs.”

Two precision points matter for anyone reading coverage of the decision. First, the district courts in these cases denied the preliminary injunctions, and the panel affirmed — the Fifth Circuit did not reverse an injunction in these appeals. Second, both opinions are unpublished under Fifth Circuit Rule 47.5, which makes them persuasive rather than binding precedent — but they end this litigation unless a petition for rehearing en banc or Supreme Court review is filed and granted.

Why the FDA delisted the drugs

The FDA adds drugs to the national shortage list when supply cannot meet demand; while a drug is listed, the FD&C Act’s compounding prohibition is “temporarily suspended,” which is what made the compounded-GLP-1 market lawful in the first place. As the opinions explain, the agency removed the products once manufacturers demonstrated they could meet demand:

• Wegovy was added March 31, 2022; Ozempic on Aug. 23, 2022.
• Mounjaro was added December 2022; Zepbound in April 2024.
• The FDA resolved the tirzepatide shortage in October 2024, confirmed it in December 2024, and removed semaglutide in early 2025.

The FDA concluded Lilly’s supply would “meet or exceed projected demand” — Lilly spent roughly $23 billion building and expanding U.S. and European manufacturing capacity and won approval to sell single-dose vials alongside pens — and that Novo Nordisk could supply 5.8 million packages of semaglutide per month. The court found the delistings were neither arbitrary nor capricious and that any APA procedural error was harmless.

What is still legal: patient-specific compounding (503A)

The ruling does not end all GLP-1 compounding. A state-licensed pharmacy can still fill an individual prescription for a named patient under the 503A pathway where there is a documented clinical reason the approved product does not work for that patient — for example, a genuine allergy to an inactive ingredient in the brand product, or a dose the approved strengths cannot deliver. Medical News Today / Vital Signs Today noted that “the ruling does not affect existing compounding for individual patients with specific medical needs, but bulk production for general use is prohibited.” PeptideDeck’s analysis reaches the same conclusion: patient-specific 503A compounding “survives, but on a much narrower legal footing.”

The nuance that matters: “personalization” is a legal test, not a marketing word. Wanting a lower price is not a clinical reason. A pharmacy adding an ingredient or filling an in-between dose must be able to document a clinical judgment that holds up. Programs that market “personalization” while functionally selling a standard product at scale carry the regulatory risk — the same line the FDA has drawn in its guidance on compounding during GLP-1 supply stabilization.

What is no longer legal: bulk compounding for general use (503B)

What ends with the ruling is the bulk (503B) channel — outsourcing facilities that compounded semaglutide and tirzepatide in volume, without individual patient-specific prescriptions, and sold them to clinics and telehealth programs at scale and at lower prices. That business model rested entirely on the shortage-list exception; with the delisting affirmed, bulk compounding for general use is no longer lawful. The FDA’s enforcement runway after each delisting — 60 or 90 days, depending on the type of compounder — was designed “to avoid unnecessary disruption to patient treatment” and has long since passed.

This is the last legal avenue: the two Fifth Circuit rulings shut the door on the compounding industry’s challenge to the delistings. For the regulatory history that led here — the DDC nomination, the proposed 503B bulks-list exclusion, and the enforcement wave — see our earlier explainer on the compounded GLP-1 ban: Novo and Lilly’s FDA push, the FDA’s proposed 503B exclusion, the FDA signal on peptide compounding, and the FDA compounding enforcement intensification. Our FDA timeline tracker maps the full sequence.

What patients currently using compounded GLP-1s should do

For patients who have been using compounded semaglutide or tirzepatide, the practical question is whether their prescription qualifies under the narrower standard:

• Ask your prescriber whether your prescription meets the documented-need standard — an ingredient allergy, a dose the approved product cannot deliver, or another documented clinical reason. If it does, a state-licensed pharmacy can still fill it under 503A.
• If it does not qualify, discuss transitioning to an FDA-approved option — Ozempic, Wegovy, Mounjaro, or Zepbound — and what that means for your coverage and cost. Brand-name GLP-1s often cost over $1,000 per month without insurance, and many plans do not cover them for weight loss.
• Do not buy from unverified sellers or “research” suppliers. Compounded drugs should only come from a licensed pharmacy acting on a valid prescription for you. The state-by-state regulatory picture and our compounding pharmacy checklist explain how the patchwork of state and federal rules is tightening.

Price and access implications

The ruling removes the last legal avenue for reversing the GLP-1 delistings, which means cheap, mass-produced compounded copies are going away. That can mean higher out-of-pocket costs or fewer options for patients who relied on them. It does not eliminate all compounding — patient-specific 503A prescriptions for documented medical needs remain lawful — but it forecloses the volume channel that made compounded GLP-1s broadly available during the shortage years. At the same time, research on the approved products at the center of this fight keeps moving: a Swedish cohort study published this summer linked semaglutide use to fewer psychiatric hospitalizations in bipolar disorder.

The market is already responding: telehealth and clinic programs that built offerings around bulk-compounded product are shifting strategy — Hims & Hers, for example, has said it will focus on already-permitted peptides rather than GLP-1 copies. The court’s decision also confirms the FDA’s framework for managing the shortage list, setting the template for how future delistings — including the remaining liraglutide shortage — will be treated. What the consultation looks like inside those programs is set out in GLP-1 Telehealth: Fewer Than a Third Consult a Doctor.

The pricing fallout arrived the day after the ruling. On Aug 28, 2026, DirectMeds announced expanded access to doctor-guided GLP-1 programs starting at $249/month for sublingual semaglutide (injectable semaglutide or tirzepatide from $297/month) with no separate membership fees or hidden charges — the latest in a wave of transparent-priced telehealth programs competing for patients who previously relied on cheap compounded supply. For context, most major platforms now pair FDA-approved brand GLP-1s with a membership fee on top: Hims charges from $149/mo for Wegovy pill or Foundayo pills plus a $149/mo membership (first month $39), Mochi runs $79/mo membership with branded meds from $149–299, and Ro Body is $39 first month then $74/mo prepaid with branded GLP-1s billed separately (roughly $900–1,000/mo cash). Brand-name GLP-1s still often land over $1,000/month without insurance — the new sub-$300 telehealth tiers are the counterweight. For the full current comparison, see our GLP-1 telehealth pricing in 2026 guide. How to read that table — who read each price, and when — is set out in How to Tell If a GLP-1 Price Comparison Is Trustworthy.

FAQ

Is compounded semaglutide still legal in 2026?

Not as a general matter. On August 27, 2026, the Fifth Circuit upheld the FDA’s removal of semaglutide (Ozempic, Wegovy) from the drug shortage list, ending the legal basis for bulk compounding of copycat semaglutide. What remains lawful: a licensed pharmacy compounding semaglutide for an individual patient with a valid prescription and a documented medical need the approved product cannot meet (the 503A pathway). Shortage-based mass production for general inventory is over.

Can I still get compounded Ozempic?

Only through patient-specific compounding. “Ozempic” is the FDA-approved brand; a pharmacy cannot mass-produce a copy of it on a shortage rationale anymore. But a prescriber can still write an individual prescription for compounded semaglutide where there is a documented clinical need — such as an allergy to an ingredient in the brand product — and a state-licensed pharmacy can fill it. Patients currently using compounded semaglutide should ask their prescriber whether they qualify under the documented-need standard or need to transition to an FDA-approved option.

Can I still get compounded tirzepatide?

The same split applies. The Fifth Circuit’s August 27, 2026 ruling (case 25-10600) affirmed the FDA’s delisting of tirzepatide products Mounjaro and Zepbound, so bulk compounding of tirzepatide for general use is no longer lawful. Patient-specific 503A compounding for an individual patient with a documented medical need remains legal. As with semaglutide, wanting a lower price is not by itself a qualifying clinical reason.

What does the compounded GLP-1 ruling mean?

The Fifth Circuit affirmed the FDA’s removal of semaglutide and tirzepatide from the national drug shortage list, so bulk compounding of these GLP-1s for general use is no longer lawful. Patient-specific 503A compounding for documented medical needs remains legal. Both opinions were issued unpublished, making them persuasive rather than binding precedent — but they end the compounding industry’s challenge to the delistings unless further review is granted.

Bottom line

Bulk-compounded semaglutide and tirzepatide are no longer lawful for general use as of the Fifth Circuit’s August 27, 2026 affirmance; patient-specific 503A compounding for documented medical needs remains legal. If you use a compounded GLP-1, talk to your prescriber about whether your prescription qualifies — and about approved alternatives, coverage, and cost. For the full regulatory timeline, see our FDA tracker and the compounded GLP-1 explainer. If you are still weighing a compounded option, what to ask before getting compounded GLP-1s or peptides is the checklist to run first.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.